These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33902820)

  • 21. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
    McMurray JJV; Jackson AM; Lam CSP; Redfield MM; Anand IS; Ge J; Lefkowitz MP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Rizkala AR; Sabarwal SV; Shah AM; Shah SJ; Shi VC; van Veldhuisen DJ; Zannad F; Zile MR; Cikes M; Goncalvesova E; Katova T; Kosztin A; Lelonek M; Sweitzer N; Vardeny O; Claggett B; Jhund PS; Solomon SD
    Circulation; 2020 Feb; 141(5):338-351. PubMed ID: 31736337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
    Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization.
    Bhatt AS; Claggett BL; Packer M; Lefkowitz MP; Zile MR; McMurray JJV; Solomon SD; Vaduganathan M
    J Card Fail; 2021 Sep; 27(9):1027-1030. PubMed ID: 34133969
    [No Abstract]   [Full Text] [Related]  

  • 24. Monitoring the dynamics of clinical and laboratory markers of chronic heart failure during 12 months of sacubitril/valsartan treatment.
    Čepelová J; Malý M; Daněk J; Malý M
    Vnitr Lek; 2021; 67(4):212-217. PubMed ID: 34275306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerability and efficacy of sacubitril/valsartan in clinical practice.
    Nandal S; Chow CL; Hannah V; Vaddadi G; Van Gaal W
    Intern Med J; 2021 Jan; 51(1):87-92. PubMed ID: 31908131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
    JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the Effect of Sacubitril/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy.
    Ioannou A; Metaxa S; Simon S; Mandal AKJ; Missouris CG
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):755-762. PubMed ID: 32648169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
    Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
    Piepoli MF; Hussain RI; Comin-Colet J; Dosantos R; Ferber P; Jaarsma T; Edelmann F
    Eur J Heart Fail; 2021 Jan; 23(1):127-135. PubMed ID: 33314487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure.
    Carballo D; Stirnemann J; Garin N; Marti C; Serratrice J; Carballo S
    ESC Heart Fail; 2020 Jun; 7(3):1282-1290. PubMed ID: 32167679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data.
    Gagne JJ; Tsacogianis T; Bruce Wirta S; Rogers JR; Calado F; Chang CL; Turner SJ; Schlienger RG; Balas B; Abdurrob A; Najafzadeh M; Wang SV
    J Comp Eff Res; 2018 Nov; 7(11):1073-1082. PubMed ID: 30156128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacubitril/Valsartan in Clinical Practice: A Report of 2 Cases.
    Cosentino E
    Cardiology; 2017; 138 Suppl 1():7-10. PubMed ID: 29262399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
    Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
    J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sacubitril-Valsartan in a routine community population: attention to volume status critical to achieving target dose.
    Pharithi RB; Ferre-Vallverdu M; Maisel AS; O'Connell E; Walshe M; Sweeney C; Barton J; McDonald K; O'Hare D; Watson C; Gallagher J; Ledwidge M; McDonald K
    ESC Heart Fail; 2020 Feb; 7(1):158-166. PubMed ID: 31903729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.